<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455806</url>
  </required_header>
  <id_info>
    <org_study_id>ESAMOX_01_2007</org_study_id>
    <secondary_id>EudraCT Numberr 2006-004323-10</secondary_id>
    <nct_id>NCT00455806</nct_id>
  </id_info>
  <brief_title>Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection</brief_title>
  <acronym>ESAMOX</acronym>
  <official_title>Randomized, Controlled, Multicenter Phase III Study for the Efficacy and Tolerability of Triple Therapy With Esomeprazole, Moxifloxacin and Amoxicillin for Rescue Therapy of Helicobacter Pylori Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Successful H. pylori eradication therapy remains a challenge in medical practice. Despite
      promising data for first-line, second-line and rescue treatment options based on clinical
      trials as well as guidelines and expert recommendations, success rates can often not be
      reproduced in general practice. Rescue options for patients with failed initial or
      second-line therapy are definitely needed. The new fluoroquinolone moxifloxacin may represent
      an effective and save treatment option (in combination with a PPI and amoxicillin) for rescue
      therapy of H- pylori positive patients.However, optimal duration of therapy (7-day course vs
      14-day course) has to be determined
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Successful H. pylori eradication therapy remains a challenge in medical practice. Currently,
      a PPI - based triple therapy containing clarithromycin, amoxicillin or nitroimidazole given
      for 7 days is the recommended first line treatment approach with an expected eradication
      success rate of approximately 80%. As second-line treatment option in case of failure, a
      RBC-based quadruple therapy is currently recommended curing another 80% of patients, leaving
      a subset of patients with persistent H. pylori infection. Resistance to fluoroquinolones is
      low in most countries,hence these compounds are potential candidates for second-line and
      rescue treatment. The new fluoroquinolone moxifloxacin launched by Bayer in 1999 for the
      treatment of respiratory tract infections, has a broad antibacterial spectrum comparable to
      levofloxacin but fewer phototoxic and central nervous system excitatory effects. The possible
      role of moxifloxacin in H. pylori eradication is since under clinical investigation
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">February 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of a combination of esomeprazole (E), moxifloxacin (M) and amoxicillin (A) for third line therapy of H. pylori infection.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of EMA 7 days versus EMA 14 days. Hypothesis: superiority of EMA 14 days 4 weeks after end of eradication therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability,safety, post treatment resistance, influence of host genetics (CYP status) and pathogenicity factors of H. pylori on treatment success.</measure>
  </secondary_outcome>
  <enrollment>132</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <condition>Chronic Gastritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>esomeprazole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male/female, age &gt;/=18 years

          -  Helicobacter pylori infection proven by histology and culture

          -  indication for eradication therapy according to the Maastricht-III

          -  at least one failed prior eradication attempt

          -  pretherapeutic resistance testing (culture)

          -  written informed consent

        Exclusion Criteria:

          -  in vitro resistance to moxifloxacin or amoxicillin

          -  current complicated peptic ulcer disease

          -  daily intake of NSAIDs

          -  co-medication with drugs known to interact with the study medication

          -  history of gastric surgery/vagotomy

          -  medical treatment for depression, known suicide attempt

          -  severe cardiological diseases such as bradyarrythmia, QT changes

          -  malignant disease

          -  gravidity, nursing

          -  women with child bearing potential must perform contraceptive measures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Miehlke, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Department I, Gastroenterology, Universityhospital, Technical University Dresden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Lehn, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institue for Medical Microbiology, University of Regensburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enno Jacobs, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute for Medical Microbiology, Technical University of Dresden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manfred Stolte, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute for Pathology, Klinikum Bayreuth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan Miehlke, MD, PhD</last_name>
    <phone>+493514585645</phone>
    <email>stephan.miehlk@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Morgner, MD, PhD</last_name>
    <phone>+493514584460</phone>
    <email>andrea.morgner-miehlke@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gastroenterologist, private praxis</name>
      <address>
        <city>Cologne</city>
        <zip>51063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elke Bästlein, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elke Bästlein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Med. Dept. I, Gastroenterology, University Hospital, Technical University of Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Morgner-Miehlke, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Morgner-Miehlke, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterologist / private praxis</name>
      <address>
        <city>Görlitz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Haferland, ME</last_name>
    </contact>
    <investigator>
      <last_name>Christian Haferland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Department, University Homburg/Saar</name>
      <address>
        <city>Homburg/Saar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Treiber, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Gerhard Treiber, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Dept. I, University Hpspital Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Hellmig, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Hellmig, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterologist / private praxis</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilfried Höchter, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Josef Weingart</last_name>
    </contact_backup>
    <investigator>
      <last_name>Wilfried Höchter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Technical University of Munich, Medical Dept. II</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Meining, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Alexander Meining, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterologist / private praxis</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Neumeyer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Neumeyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Med. Department, Jung-Stilling Krankenhaus</name>
      <address>
        <city>Siegen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Leodolter, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Joachim Labenz, MD, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Andreas Leodolter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Morgner A, Labenz J, Miehlke S. Effective regimens for the treatment of Helicobacter pylori infection. Expert Opin Investig Drugs. 2006 Sep;15(9):995-1016. Review.</citation>
    <PMID>16916269</PMID>
  </reference>
  <reference>
    <citation>Miehlke S, Hansky K, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E, Bästlein E, Jacobs E, Bayerdörffer E, Lehn N, Stolte M. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther. 2006 Jul 15;24(2):395-403.</citation>
    <PMID>16842467</PMID>
  </reference>
  <reference>
    <citation>Miehlke S, Schneider-Brachert W, Bästlein E, Ebert S, Kirsch C, Haferland C, Buchner M, Neumeyer M, Vieth M, Stolte M, Lehn N, Bayerdörffer E. Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance. Aliment Pharmacol Ther. 2003 Oct 15;18(8):799-804.</citation>
    <PMID>14535873</PMID>
  </reference>
  <reference>
    <citation>Miehlke S, Bayerdörffer E, Graham DY. Treatment of Helicobacter pylori infection. Semin Gastrointest Dis. 2001 Jul;12(3):167-79. Review.</citation>
    <PMID>11478749</PMID>
  </reference>
  <reference>
    <citation>Cheon JH, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter. 2006 Feb;11(1):46-51.</citation>
    <PMID>16423089</PMID>
  </reference>
  <reference>
    <citation>Nista EC, Candelli M, Zocco MA, Cazzato IA, Cremonini F, Ojetti V, Santoro M, Finizio R, Pignataro G, Cammarota G, Gasbarrini G, Gasbarrini A. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2005 May 15;21(10):1241-7.</citation>
    <PMID>15882245</PMID>
  </reference>
  <reference>
    <citation>Di Caro S, Ojetti V, Zocco MA, Cremonini F, Bartolozzi F, Candelli M, Lupascu A, Nista EC, Cammarota G, Gasbarrini A. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2002 Mar;16(3):527-32.</citation>
    <PMID>11876707</PMID>
  </reference>
  <reference>
    <citation>Mégraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2003 Jun 1;17(11):1333-43. Review.</citation>
    <PMID>12786627</PMID>
  </reference>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2007</study_first_submitted>
  <study_first_submitted_qc>April 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2007</study_first_posted>
  <last_update_submitted>April 3, 2007</last_update_submitted>
  <last_update_submitted_qc>April 3, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2007</last_update_posted>
  <keyword>Helicobacter pylori</keyword>
  <keyword>rescue therapy</keyword>
  <keyword>eradication therapy</keyword>
  <keyword>esomeprazole</keyword>
  <keyword>moxifloxacin</keyword>
  <keyword>resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

